Results 141 to 150 of about 23,603,276 (341)

Type I Interferon Drives Dysfunction of a Distinct CD8+ HLA‐DRB1+ T Cell Subset in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is characterized by type I interferon (IFN) signaling and adaptive immune dysregulation. We previously identified hypomethylation of HLA‐DRB1 and STAT1 in SLE CD8+ T cells, enabling aberrant IFN‐driven HLA‐DRB1 expression and expansion of a distinct CD8+ T cell subset. This study characterized CD8+ HLA‐DRB1+
Huizhong Long   +3 more
wiley   +1 more source

Exploiting the retrograde transport of disarmed toxins for the delivery of exogenous antigens into MHC class 1 presentation pathway [PDF]

open access: yes
The targeting of exogenous antigen into the MHC class 1-restricted presentation pathway is required for the induction of cytotoxic T lymphocytes (CTL) which have been shown to be an important component of the protective response to intracellular ...
Noakes, Karen
core  

Development of a sample bank and clinical database for the retrospective analysis of unrelated bone marrow transplants: a pilot study of 138 transplants using RSCA for high resolution HLA matching. [PDF]

open access: yes, 2005
The Anthony Nolan Register provides donors for allogeneic stem cell transplantation for haematological disorders. A clinical database and sample bank were established for the ongoing analysis of transplants from Register donors.
Pay, A.L.P.
core  

Single‐cell RNA sequencing of peripheral blood defines two immunological subtypes of Sjögren's disease distinguished by anti‐SSA antibodies and aberrant B cell populations

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Sjögren's disease (SjD) is a heterogeneous autoimmune disorder characterized by substantial clinical and molecular diversity. This heterogeneity raises key questions regarding the existence of distinct pathogenic mechanisms underlying disease subtypes.
Geoffrey Urbanski   +15 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

IPD - the Immuno Polymorphism Database [PDF]

open access: yes, 2005
The Immuno Polymorphism Database (IPD) (http://www.ebi.ac.uk/ipd/) is a set of specialist databases related to the study of polymorphic genes in the immune system.
Marsh, S.G.E.   +3 more
core  

Protocol for measuring exogenous antigen presentation triggered by membranes of bone marrow-derived dendritic cell purified phagosomes

open access: yesSTAR Protocols
Summary: Dendritic cells are potent antigen-presenting cells that initiate T cell responses by presenting exogenous antigens associated with major histocompatibility complex (MHC) class I and MHC class II molecules.
Facundo Garrido   +3 more
doaj   +1 more source

Expression of class I and class II major histocompatibility antigens in normal and transplanted human heart.

open access: yesTransplantation, 1986
Marlene L. Rose   +4 more
semanticscholar   +1 more source

Prediction of Human Serum Concentration–Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti‐Drug Antibodies

open access: yesBiopharmaceutics &Drug Disposition, EarlyView.
This study identified new optimal allometric scaling exponents for human PK prediction of monoclonal antibodies with linear PKs from marmoset PK data. In addition, immunogenicity in common marmosets was evaluated following the repeated dose of golimumab and ustekinumab, minimal anti‐drug antibodies were detected.
Ayaka Tajiri   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy